Agilent Technologies (A) said Monday that its PD-L1 IHC 28-8 pharmDx kit was approved for two new companion diagnostic indications in the European Union.
The kit is now approved as a companion diagnostic test for malignant melanoma and non-small cell lung cancer, Agilent said.
The new approvals bring the kit's total approved indications in Europe to nine, the company said.
Price: 123.91, Change: -2.79, Percent Change: -2.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.